The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia
- PMID: 20550658
- PMCID: PMC2898740
- DOI: 10.1186/1471-244X-10-47
The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia
Abstract
Background: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics; nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time.
Methods: In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 13) or novel antipsychotics (n = 26) at baseline and at two years after.
Results: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. Patients taking atypical antipsychotics did not show greater cognitive enhancement over two years than patients taking conventional antipsychotics.
Conclusions: Although long-term antipsychotic treatment slightly improved cognitive function, the switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of these cognitive deficits.
Similar articles
-
[Cognition, schizophrenia and the effect of antipsychotics].Encephale. 2006 May-Jun;32(3 Pt 1):341-50. doi: 10.1016/s0013-7006(06)76162-0. Encephale. 2006. PMID: 16840928 Review. French.
-
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.Schizophr Res. 2001 Mar 1;48(1):17-28. doi: 10.1016/s0920-9964(00)00112-2. Schizophr Res. 2001. PMID: 11278151 Review.
-
Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study.Arch Clin Neuropsychol. 2008 May;23(3):271-82. doi: 10.1016/j.acn.2007.12.005. Epub 2008 Feb 12. Arch Clin Neuropsychol. 2008. PMID: 18272323 Clinical Trial.
-
The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings.J Clin Psychiatry. 2003 May;64(5):524-31. doi: 10.4088/jcp.v64n0505. J Clin Psychiatry. 2003. PMID: 12755654 Clinical Trial.
-
Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.J Clin Psychiatry. 1999;60 Suppl 23:25-8. J Clin Psychiatry. 1999. PMID: 10625197 Review.
Cited by
-
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.Med Sci Monit. 2012 Jan;18(1):CR44-49. doi: 10.12659/msm.882202. Med Sci Monit. 2012. PMID: 22207119 Free PMC article.
-
Clinical outcomes and anti-inflammatory mechanisms predict maximum heart rate improvement after physical activity training in individuals with psychiatric disorders and comorbid obesity.PLoS One. 2025 Jan 3;20(1):e0313759. doi: 10.1371/journal.pone.0313759. eCollection 2025. PLoS One. 2025. PMID: 39752432 Free PMC article.
-
Specific immune-inflammatory profiles and neurocognitive deficits predict illness trajectories in people with type 2 diabetes mellitus or psychiatric disorders.Brain Behav Immun Health. 2025 Feb 13;44:100962. doi: 10.1016/j.bbih.2025.100962. eCollection 2025 Mar. Brain Behav Immun Health. 2025. PMID: 40046177 Free PMC article.
-
Immune-Inflammatory Biomarkers Predict Cognition and Social Functioning in Patients With Type 2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A 1-Year Follow-Up Study.Front Neurol. 2022 Jun 2;13:883927. doi: 10.3389/fneur.2022.883927. eCollection 2022. Front Neurol. 2022. PMID: 35720107 Free PMC article.
-
Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia.Front Psychol. 2020 Nov 25;11:525231. doi: 10.3389/fpsyg.2020.525231. eCollection 2020. Front Psychol. 2020. PMID: 33324271 Free PMC article.
References
-
- Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544–549. - PubMed
-
- Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry. 1991;48:239–246. - PubMed